In Brief: Schering-Plough's Nasonex
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's Nasonex: NDA filed Sept. 30 for the prescription mometasone furoate aqueous nasal spray. Schering is seeking use of the once-daily Nasonex for "prophylaxis and treatment of symptoms of seasonal allergic rhinitis and the treatment of perennial rhinitis in adults and adolescents 12 years of age and older," the company reports. Mometasone furoate also is being developed in dry powder and metered-dose inhaler formulations for bronchial asthma...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning